Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2016

01-04-2016 | Original Article

Upregulation of RICTOR gene transcription by the proinflammatory cytokines through NF-κB pathway contributes to the metastasis of renal cell carcinoma

Authors: Bo Sun, Liwei Chen, Hui Fu, Lin Guo, Hua Guo, Ning Zhang

Published in: Tumor Biology | Issue 4/2016

Login to get access

Abstract

Metastasis accounts for more than 50 % of deaths among renal cell carcinoma (RCC) patients, and therefore, it is important to study the biology of metastasis and identify metastasis-associated biomarkers for risk prognosis and stratification of patients for an individualized therapy of RCC. In cultured RCC cells, knockdown of Rictor by short hairpin RNA (shRNA) inhibited cell migration and invasion, probably due to impairments in activation of Akt. Pretreatment with tumor necrosis factor α (TNFα) or interleukin 6 (IL-6) enhanced the expression of Rictor and the migration of renal cancer cells. Mechanistic analysis showed that TNFα induced the activation of NF-κB in RCC cells. Luciferase reporter analysis revealed a NF-κB responding element (−301 to −51 bp) at the promoter region of Rictor. Chromatin immunoprecipitation (ChIP) analysis further confirmed that TNFα-induced binding of p65 with the promoter of Rictor. In a xenograft model, knockdown of Rictor-blocked RCC cells metastasis to the mouse lungs and livers. Taken together, our results suggest that the proinflammatory cytokine TNFα promotes the expression of Rictor through the NF-κB pathway.
Literature
1.
2.
3.
Wysocki PJ. mtor in renal cell cancer: modulator of tumor biology and therapeutic target. Expert Rev Mol Diagn. 2009;9:231–41.CrossRefPubMed
4.
Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30:1073–81.CrossRefPubMed
5.
6.
Multhoff G, Molls M, Radons J. Chronic inflammation in cancer development. Front Immunol. 2011;2:98.PubMed
7.
Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014;2014:149185.CrossRefPubMedPubMedCentral
8.
Ho MY, Tang SJ, Chuang MJ, Cha TL, Li JY, Sun GH, et al. TNF-α induces epithelial-mesenchymal transition of renal cell carcinoma cells via a gsk3beta-dependent mechanism. Mol Cancer Res. 2012;10:1109–19.CrossRefPubMed
9.
Hamaguchi T, Wakabayashi H, Matsumine A, Sudo A, Uchida A. TNF inhibitor suppresses bone metastasis in a breast cancer cell line. Biochem Biophys Res Commun. 2011;407:525–30.CrossRefPubMed
10.
Yadav A, Kumar B, Datta J, Teknos TN, Kumar P. IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the jak-stat3-snail signaling pathway. Mol Cancer Res. 2011;9:1658–67.CrossRefPubMedPubMedCentral
11.
Chang Q, Bournazou E, Sansone P, Berishaj M, Gao SP, Daly L, et al. The IL-6/JAK/stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia. 2013;15:848–62.CrossRefPubMedPubMedCentral
12.
Mikami S, Mizuno R, Kosaka T, Saya H, Oya M, Okada Y. Expression of TNF-α and CD44 is implicated in poor prognosis, cancer cell invasion, metastasis and resistance to the sunitinib treatment in clear cell renal cell carcinomas. Int J Cancer. 2015;136:1504–14.CrossRefPubMed
13.
Jung HY, Fattet L, Yang J. Molecular pathways: linking tumor microenvironment to epithelial-mesenchymal transition in metastasis. Clin Cancer Res. 2015;21:962–8.CrossRefPubMed
14.
15.
16.
Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. NF-kappab functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431:461–6.CrossRefPubMed
17.
Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, et al. Ikkβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004;118:285–96.CrossRefPubMed
18.
Mauad TH, van Nieuwkerk CM, Dingemans KP, Smit JJ, Schinkel AH, Notenboom RG, et al. Mice with homozygous disruption of the mdr2 p-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am J Pathol. 1994;145:1237–45.PubMedPubMedCentral
19.
Xue C, Wyckoff J, Liang F, Sidani M, Violini S, Tsai KL, et al. Epidermal growth factor receptor overexpression results in increased tumor cell motility in vivo coordinately with enhanced intravasation and metastasis. Cancer Res. 2006;66:192–7.CrossRefPubMed
20.
Zhang B, Gu F, She C, Guo H, Li W, Niu R, et al. Reduction of Akt2 inhibits migration and invasion of glioma cells. Int J Cancer. 2009;125:585–95.CrossRefPubMed
21.
Guo H, Gu F, Li W, Zhang B, Niu R, Fu L, et al. Reduction of protein kinase C ζ inhibits migration and invasion of human glioblastoma cells. J Neurochem. 2009;109:203–13.CrossRefPubMed
22.
Liu Y, Wang J, Wu M, Wan W, Sun R, Yang D, et al. Down-regulation of 3-phosphoinositide-dependent protein kinase-1 levels inhibits migration and experimental metastasis of human breast cancer cells. Mol Cancer Res. 2009;7:944–54.CrossRefPubMed
23.
Figlin RA, Kaufmann I, Brechbiel J. Targeting PI3k and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors. Int J Cancer. 2013;133:788–96.CrossRefPubMed
24.
Polivka Jr J, Janku F. Molecular targets for cancer therapy in the PI3K/Akt/mTOR pathway. Pharmacol Ther. 2014;142:164–75.CrossRefPubMed
25.
Francipane MG, Lagasse E. mTOR pathway in colorectal cancer: an update. Oncotarget. 2014;5:49–66.PubMed
26.
27.
Wullschleger S, Loewith R, Hall MN. Tor signaling in growth and metabolism. Cell. 2006;124:471–84.CrossRefPubMed
28.
Brunn GJ, Hudson CC, Sekulic A, Williams JM, Hosoi H, Houghton PJ, et al. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science. 1997;277:99–101.CrossRefPubMed
29.
Burnett PE, Barrow RK, Cohen NA, Snyder SH, Sabatini DM. RAFT1 phosphorylation of the translational regulators p70 s6 kinase and 4E-BP1. Proc Natl Acad Sci U S A. 1998;95:1432–7.CrossRefPubMedPubMedCentral
30.
Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004;14:1296–302.CrossRefPubMed
31.
Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, et al. Mammalian tor complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol. 2004;6:1122–8.CrossRefPubMed
32.
Janes MR, Vu C, Mallya S, Shieh MP, Limon JJ, Li LS, et al. Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia. 2013;27:586–94.CrossRefPubMed
33.
Bhagwat SV, Gokhale PC, Crew AP, Cooke A, Yao Y, Mantis C, et al. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol Cancer Ther. 2011;10:1394–406.CrossRefPubMed
34.
Naing A, Aghajanian C, Raymond E, Olmos D, Schwartz G, Oelmann E, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. Br J Cancer. 2012;107:1093–9.CrossRefPubMedPubMedCentral
35.
Zhang F, Zhang X, Li M, Chen P, Zhang B, Guo H, et al. mTOR complex component Rictor interacts with PKCζ and regulates cancer cell metastasis. Cancer Res. 2010;70:9360–70.CrossRefPubMed
36.
Liu Z, Garrard WT. Long-range interactions between three transcriptional enhancers, active Vκ gene promoters, and a 3′ boundary sequence spanning 46 kilobases. Mol Cell Biol. 2005;25:3220–31.CrossRefPubMedPubMedCentral
37.
Sun R, Gao P, Chen L, Ma D, Wang J, Oppenheim JJ, et al. Protein kinase C ζ is required for epidermal growth factor-induced chemotaxis of human breast cancer cells. Cancer Res. 2005;65:1433–41.CrossRefPubMed
38.
Heyninck K, Beyaert R. Crosstalk between NF-κB-activating and apoptosis-inducing proteins of the TNF-receptor complex. Mol Cell Biol Res Commun. 2001;4:259–65.CrossRefPubMed
39.
40.
Li D, Zhong Y, Zhou Y, Sun H, Zheng X, Zhao C, et al. Autocrine TNF-α-mediated NF-κB activation is a determinant for evasion of CD40-induced cytotoxicity in cancer cells. Biochem Biophys Res Commun. 2013;436:467–72.CrossRefPubMed
41.
Prabhavathy D, Subramanian CK, Karunagaran D. Re-expression of HPV16 E2 in SiHa (human cervical cancer) cells potentiates NF-κB activation induced by TNF-α concurrently increasing senescence and survival. Biosci Rep. 2015;35. doi:10.​1042/​BSR20140160.
42.
De Simone V, Franze E, Ronchetti G, Colantoni A, Fantini MC, Di Fusco D, et al. Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-κB to promote colorectal cancer cell growth. Oncogene. 2015;34:3493–503.CrossRefPubMed
43.
Lin CM, Shyu KG, Wang BW, Chang H, Chen YH, Chiu JH. Chrysin suppresses IL-6-induced angiogenesis via down-regulation of JAK1/STATt3 and VEGF: an in vitro and in ovo approach. J Agric Food Chem. 2010;58:7082–7.CrossRefPubMed
44.
Shinohara N, Nonomura K, Abe T, Maruyama S, Kamai T, Takahashi M, et al. A new prognostic classification for overall survival in Asian patients with previously untreated metastatic renal cell carcinoma. Cancer Sci. 2012;103:1695–700.CrossRefPubMed
45.
Escudier B, Albiges L, Sonpavde G. Optimal management of metastatic renal cell carcinoma: current status. Drugs. 2013;73:427–38.CrossRefPubMed
46.
Albouy B, Gross Goupil M, Escudier B, Massard C. Renal cell carcinoma management and therapies in 2010. Bull Cancer. 2010;97:17–28.PubMed
47.
Legramanti S, Antonelli A, Ferrari V, Arrighi N, Corti S, Zanotelli T, et al. Simeone C: [results of targeted therapies for m1 renal cell carcinoma: our experience]. Urologia. 2012;79 Suppl 19:72–5.PubMed
48.
Bashir T, Cloninger C, Artinian N, Anderson L, Bernath A, Holmes B, et al. Conditional astroglial Rictor overexpression induces malignant glioma in mice. PLoS One. 2012;7:e47741.CrossRefPubMedPubMedCentral
49.
Bera A, Das F, Ghosh-Choudhury N, Kasinath BS, Abboud HE, Choudhury GG. Microrna-21-induced dissociation of PDCD4 from Rictor contributes to Akt-IKKβ-mTORC1 axis to regulate renal cancer cell invasion. Exp Cell Res. 2014;328:99–117.CrossRefPubMedPubMedCentral
50.
51.
Granado-Serrano AB, Martin MA, Bravo L, Goya L, Ramos S. Quercetin attenuates TNF-induced inflammation in hepatic cells by inhibiting the NF-κB pathway. Nutr Cancer. 2012;64:588–98.CrossRefPubMed
52.
53.
Tebbutt NC, Giraud AS, Inglese M, Jenkins B, Waring P, Clay FJ, et al. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STATt-mediated trefoil gene activation in gp130 mutant mice. Nat Med. 2002;8:1089–97.CrossRefPubMed
54.
Katsha A, Soutto M, Sehdev V, Peng D, Washington MK, Piazuelo MB, et al. Aurora kinase a promotes inflammation and tumorigenesis in mice and human gastric neoplasia. Gastroenterology 2013;145:1312-1322 e1311-1318.
55.
van der Woude CJ, Moshage H, Homan M, Kleibeuker JH, Jansen PL, van Dekken H. Expression of apoptosis related proteins during malignant progression in chronic ulcerative colitis. J Clin Pathol. 2005;58:811–4.CrossRefPubMedPubMedCentral
56.
de Vivar Chevez AR, Finke J, Bukowski R. The role of inflammation in kidney cancer. Adv Exp Med Biol. 2014;816:197–234.CrossRefPubMed
57.
Lu Y, Zhao X, Luo G, Shen G, Li K, Ren G, et al. Thioredoxin-like protein 2b facilitates colon cancer cell proliferation and inhibits apoptosis via NF-κB pathway. Cancer Lett. 2015;363:119–26.CrossRefPubMed
58.
Luo Y, Wang SX, Zhou ZQ, Wang Z, Zhang YG, Zhang Y, et al. Apoptotic effect of genistein on human colon cancer cells via inhibiting the nuclear factor-kappa B (NF-κB) pathway. Tumour Biol. 2014;35:11483–8.CrossRefPubMed
59.
Xia J, Wang F, Wang L, Fan Q. Elevated serine protease HTRA1 inhibits cell proliferation, reduces invasion, and induces apoptosis in esophageal squamous cell carcinoma by blocking the nuclear factor-κb signaling pathway. Tumour biol. 2013;34:317–28.CrossRefPubMed
Metadata
Title
Upregulation of RICTOR gene transcription by the proinflammatory cytokines through NF-κB pathway contributes to the metastasis of renal cell carcinoma
Authors
Bo Sun
Liwei Chen
Hui Fu
Lin Guo
Hua Guo
Ning Zhang
Publication date
01-04-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4296-z

Other articles of this Issue 4/2016

Tumor Biology 4/2016 Go to the issue

Original Article

FGF2-mediated reciprocal tumor cell-endothelial cell interplay contributes to the growth of chemoresistant cells: a potential mechanism for superficial bladder cancer recurrence

Original Article

Green tea polyphenol EGCG suppresses osteosarcoma cell growth through upregulating miR-1

Original Article

Secretome of human bone marrow mesenchymal stem cells: an emerging player in lung cancer progression and mechanisms of translation initiation

Original Article

Emerging prognostic markers related to mesenchymal characteristics of poorly differentiated breast cancers

Original Article

Mitotic arrest deficient-like 1 is correlated with poor prognosis in small-cell lung cancer after surgical resection

Original Article

The role of peptidylarginine deiminase 4 in ovarian cancer cell tumorigenesis and invasion
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits